MCLENA-1: A Phase II Clinical Trial for the Assessment of Safety, Tolerability, and Efficacy of Lenalidomide in Patients with Mild Cognitive Impairment Due to Alzheimer’s Disease

MCLENA-1: A Phase II Clinical Trial for the Assessment of Safety, Tolerability, and Efficacy of Lenalidomide in Patients with Mild Cognitive Impairment Due to Alzheimer’s Disease

Boris Decourt,1 Jeffrey Wilson,2 Aaron Ritter,1 Christopher Dardis,3 Frank P DiFilippo,4 Xiaowei Zhuang,1 Dietmar Cordes,1 Garam Lee,1 Nadia D Fulkerson,1 Tessa St Rose,1 Katurah Hartley,1 Marwan N Sabbagh1 1Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA; 2Department of Econom...

Full description

Bibliographic Details
Main Authors: Decourt B, Wilson J, Ritter A, Dardis C, DiFilippo FP, Zhuang X, Cordes D, Lee G, Fulkerson ND, St Rose T, Hartley K, Sabbagh MN
Format: Article
Language:English
Published: Dove Medical Press 2020-01-01
Series:Open Access Journal of Clinical Trials
Subjects:
alzheimer’s disease
biomarkers
brain amyloid
brain imaging
clinical trial
cognition
cytokines
dementia
hematologic changes
immunomodulation
inflammation
lenalidomide.
Online Access:https://www.dovepress.com/mclena-1-a-phase-ii-clinical-trial-for-the-assessment-of-safety-tolera-peer-reviewed-article-OAJCT

Internet

https://www.dovepress.com/mclena-1-a-phase-ii-clinical-trial-for-the-assessment-of-safety-tolera-peer-reviewed-article-OAJCT

Similar Items